Immunotherapy for gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a 2021 update Christo KoleNikolaos CharalampakisDimitrios Schizas Review 01 September 2021 Pages: 761 - 768
Neurological disorders associated with immune checkpoint inhibitors: an association with autoantibodies Morinobu SekiShigehisa KitanoShigeaki Suzuki Review 13 September 2021 Pages: 769 - 775
Dynamic switch of immunity and antitumor effects of metformin in rat spontaneous esophageal carcinogenesis Ryohei TakeiTomoharu MiyashitaYasuhiko Yamamoto Original Article Open access 16 August 2021 Pages: 777 - 789
Correction to: Dynamic switch of immunity and antitumor effects of metformin in rat spontaneous esophageal carcinogenesis Ryohei TakeiTomoharu MiyashitaYasuhiko Yamamoto Correction Open access 07 September 2021 Pages: 791 - 793
GRIK2 is a target for bladder cancer stem-like cell-targeting immunotherapy Haruka MiyataYoshihiko HirohashiToshihiko Torigoe Original Article 18 August 2021 Pages: 795 - 806
Increased tumor-infiltrating lymphocyte density is associated with favorable outcomes in a comparative study of canine histiocytic sarcoma Jennifer A. LenzCharles-Antoine AssenmacherMatthew J. Atherton Original Article 20 August 2021 Pages: 807 - 818
No evidence that HLA genotype influences the driver mutations that occur in cancer patients Noor KherrehSiobhán ClearyCathal Seoighe Original Article Open access 21 August 2021 Pages: 819 - 827
Prognostic value of natural killer cell activity for patients with HER2 + advanced gastric cancer treated with first-line fluoropyrimidine–platinum doublet plus trastuzumab Hyungwoo ChoMin-Hee RyuYoon-Koo Kang Original Article 22 August 2021 Pages: 829 - 838
Long-term expression changes of immune-related genes in prostate cancer after radiotherapy Iris EkeMolykutty J. AryankalayilC. Norman Coleman Original Article 25 August 2021 Pages: 839 - 850
Dynamic alterations of circulating T lymphocytes and the clinical response in patients with head and neck squamous cell carcinoma treated with nivolumab Hiroe TadaHideyuki TakahashiKazuaki Chikamatsu Original Article 31 August 2021 Pages: 851 - 863
Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation Marco RussanoAlessio CortelliniDaniele Santini Original Article 31 August 2021 Pages: 865 - 874
MAIT cells numbers and frequencies in patients with acute myeloid leukemia at diagnosis: association with cytogenetic profile and gene mutations Thibault ComontMarie-Laure Nicolau-TraversEmmanuel Treiner Original Article 03 September 2021 Pages: 875 - 887
Combination therapy for hepatocellular carcinoma with diacylglycerol kinase alpha inhibition and anti-programmed cell death-1 ligand blockade Naoki OkadaKo SugiyamaAkinobu Taketomi Original Article 05 September 2021 Pages: 889 - 903
Tumor-infiltrating CD8+ T cells recognize a heterogeneously expressed functional neoantigen in clear cell renal cell carcinoma Masahiro MatsukiYoshihiko HirohashiToshihiko Torigoe Original Article 07 September 2021 Pages: 905 - 918
The pivotal role of cytotoxic NK cells in mediating the therapeutic effect of anti-CD47 therapy in mycosis fungoides Oleg KruglovLisa D. S. JohnsonOleg E. Akilov Original Article 14 September 2021 Pages: 919 - 932
Immune cell profiles in the tumor microenvironment of early-onset, intermediate-onset, and later-onset colorectal cancer Tomotaka UgaiJuha P. VäyrynenShuji Ogino Original Article 16 September 2021 Pages: 933 - 942
Association between pathogenic germline mutations in BRCA2 and ATM and tumor-infiltrating lymphocytes in primary prostate cancer Harsimar B. KaurThiago VidottoTamara L. Lotan Original Article 17 September 2021 Pages: 943 - 951
Tumor microenvironment is associated with clinical and genetic properties of diffuse gliomas and predicts overall survival Qiang-Wei WangZhao-Shi BaoYong-Jian Zhu Original Article 17 September 2021 Pages: 953 - 966
Combined treatment with anti-HER2/neu and anti-4-1BB monoclonal antibodies induces a synergistic antitumor effect but requires dose optimization to maintain immune memory for protection from lethal rechallenge Hee Yeon KimJae-Hyeog ChoiSaeGwang Park Original Article 06 January 2022 Pages: 967 - 978
Venetoclax-resistant CLL cells show a highly activated and proliferative phenotype Esteban Enrique EliasValeria Judith Sarapura MartinezRomina Gamberale Research Report 31 August 2021 Pages: 979 - 987
Analysis of T cell receptor clonotypes in tumor microenvironment identifies shared cancer-type-specific signatures Yvonne H. F. TengHong Sheng QuahN. Gopalakrishna Iyer Research Report 27 September 2021 Pages: 989 - 998
Correction to: Analysis of T cell receptor clonotypes in tumor microenvironment identifies shared cancer-type-specific signatures Yvonne H. F. TengHong Sheng QuahN. Gopalakrishna Iyer Correction 22 October 2021 Pages: 999 - 999